Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - PubMed (original) (raw)
Clinical Trial
. 2003 Jul 8;100(14):8372-7.
doi: 10.1073/pnas.1533209100. Epub 2003 Jun 25.
James C Yang, Richard M Sherry, Patrick Hwu, Suzanne L Topalian, Douglas J Schwartzentruber, Nicholas P Restifo, Leah R Haworth, Claudia A Seipp, Linda J Freezer, Kathleen E Morton, Sharon A Mavroukakis, Paul H Duray, Seth M Steinberg, James P Allison, Thomas A Davis, Steven A Rosenberg
Affiliations
- PMID: 12826605
- PMCID: PMC166236
- DOI: 10.1073/pnas.1533209100
Clinical Trial
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q Phan et al. Proc Natl Acad Sci U S A. 2003.
Abstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.
Figures
Fig. 1.
Computed axial tomography scans illustrating pretherapy disease status (Left) and complete responses (Right) for patient 13 (A and B) and patient 11 (C_–_F). Arrows show sites of metastases.
Fig. 2.
Histopathologic analyses of selected patients experiencing autoimmune events. (A) Skin biopsy (patient 2) showing severe dermatitis with epidermal spongiosis, papillary dermal edema, and a prominent inflammatory infiltrate in both the superficial and deep dermis. (B) Colon biopsy (patient 9) illustrating severe colitis with infiltration of the lamina propria with neutrophils, lymphocytes, monocytes, plasmacytes, and eosinophils suggestive of autoimmune reactions. Neutrophils and lymphocytes also infiltrate the crypts; numerous mitotic figures are seen in the epithelial cells lining the crypts. (C) Immunohistochemistry of the colon biopsy (patient 9) reveals that the majority of cells are CD3+. (D) Liver biopsy (patient 12) showing areas of necrosis and lobular inflammation with (mainly) lymphocytic infiltration into the portal triad. (Magnifications: A, ×10; B_–_D, ×20.)
Similar articles
- CTLA-4 blockade: autoimmunity as treatment.
Kapadia D, Fong L. Kapadia D, et al. J Clin Oncol. 2005 Dec 10;23(35):8926-8. doi: 10.1200/JCO.2005.07.012. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204008 No abstract available. - Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Sanderson K, et al. J Clin Oncol. 2005 Feb 1;23(4):741-50. doi: 10.1200/JCO.2005.01.128. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613700 - Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Robinson MR, et al. J Immunother. 2004 Nov-Dec;27(6):478-9. doi: 10.1097/00002371-200411000-00008. J Immunother. 2004. PMID: 15534492 - CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. Yuan J, et al. Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Cancer Immunol Immunother. 2011. PMID: 21465316 Free PMC article. Review. - Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Engelhard VH, et al. Immunol Rev. 2002 Oct;188:136-46. doi: 10.1034/j.1600-065x.2002.18812.x. Immunol Rev. 2002. PMID: 12445287 Review.
Cited by
- Isolated hypoprolactinemia: The rarest of the rare?
Khan A, Di Dalmazi G, Najafian Zahmatkeshan K, Caturegli P. Khan A, et al. Rev Endocr Metab Disord. 2024 Sep 13. doi: 10.1007/s11154-024-09901-0. Online ahead of print. Rev Endocr Metab Disord. 2024. PMID: 39271619 Review. - Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports.
Lee E, Jang JY, Yang J. Lee E, et al. Cancers (Basel). 2024 May 16;16(10):1896. doi: 10.3390/cancers16101896. Cancers (Basel). 2024. PMID: 38791974 Free PMC article. Review. - Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1.
Dillen A, Bui I, Jung M, Agioti S, Zaravinos A, Bonavida B. Dillen A, et al. Cancers (Basel). 2024 Mar 21;16(6):1237. doi: 10.3390/cancers16061237. Cancers (Basel). 2024. PMID: 38539569 Free PMC article. Review. - Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies.
Kong Y, Wang X, Qie R. Kong Y, et al. Front Oncol. 2024 Feb 28;14:1347140. doi: 10.3389/fonc.2024.1347140. eCollection 2024. Front Oncol. 2024. PMID: 38482205 Free PMC article. Review. - Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.
Ge S, Zhao Y, Liang J, He Z, Li K, Zhang G, Hua B, Zheng H, Guo Q, Qi R, Shi Z. Ge S, et al. Cancer Cell Int. 2024 Mar 12;24(1):105. doi: 10.1186/s12935-024-03211-w. Cancer Cell Int. 2024. PMID: 38475858 Free PMC article. Review.
References
- Bretscher, P. & Cohn, M. (1970) Science 169 1042-1049. - PubMed
- Schwartz, R. H. (1990) Science 248 1349-1356. - PubMed
- Brunet, J. F., Denizot, F., Luciani, M. F., Roux-Dosseto, M., Suzan, M., Mattei, M. G. & Goldstein, P. (1987) Nature 328 267-270. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials